<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043026</url>
  </required_header>
  <id_info>
    <org_study_id>UoL001456 - 4843</org_study_id>
    <nct_id>NCT04043026</nct_id>
  </id_info>
  <brief_title>The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function</brief_title>
  <acronym>RALiC</acronym>
  <official_title>Stratifying Clinical Risk in Patients With Atrial Fibrillation and Chronic Kidney Disease by Studying How Abnormalities in Clot Structure/Function and Lipoproteins Contribute to Thrombosis and Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liverpool Centre for Cardiovascular Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool John Moores University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate the role of lipids/lipoproteins as a potential cause for
      the harmful changes seen in fibrin clot properties with renal dysfunction and atrial
      fibrillation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, blinded study that will be conducted in three separate
      sub-studies. The first sub-study will evaluate differences in fibrin clot properties between
      atrial fibrillation patients with and without renal dysfunction. The primary outcome measures
      involving fibrin clot properties will be taken prior to commencing warfarin and repeated
      after six weeks of therapy. The second sub-study will assess the relationship between
      lipids/lipoproteins and fibrin clot properties among atrial fibrillation patients with and
      without renal dysfunction who are on stable doses of warfarin. Control arms will be used to
      validate the findings. The third sub-study will assess the effects of statin therapy on
      lipids/lipoproteins and fibrin clot properties in atrial fibrillation patients with renal
      dysfunction who are on warfarin. The primary outcome measures will be taken prior to
      commencing a statin and repeated after six weeks of therapy.

      Renal dysfunction is defined as eGFR &lt;50 ml/min/1.73m2 for the purposes for this trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>WP1: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test</measure>
    <time_frame>Baseline and after 6 weeks of warfarin</time_frame>
    <description>Lag time, maximum absorbance and clot lysis time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP1: Fibrin permeation analysis using validated test</measure>
    <time_frame>Baseline and after 6 weeks of warfarin</time_frame>
    <description>Permeation constant (Ks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test</measure>
    <time_frame>Baseline</time_frame>
    <description>Lag time, maximum absorbance and clot lysis time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Fibrin permeation analysis using validated test</measure>
    <time_frame>Baseline</time_frame>
    <description>Permeation constant (Ks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Low density lipoprotein fractions</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of low density lipoprotein subclass fractions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP2: Oxidised low density lipoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of oxidised low density lipoprotein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP3: Fibrin clot structure and function assessment using validated turbidity and fibrinolysis test</measure>
    <time_frame>Baseline and after 6 weeks of statin</time_frame>
    <description>Lag time, maximum absorbance and clot lysis time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP3: Fibrin permeation analysis using validated test</measure>
    <time_frame>Baseline and after 6 weeks of statin</time_frame>
    <description>Permeation constant (Ks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP3: Low density lipoprotein fractions</measure>
    <time_frame>Baseline and after 6 weeks of statin</time_frame>
    <description>Measure of low density lipoprotein subclass fractions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WP3: Oxidised low density lipoprotein</measure>
    <time_frame>Baseline and after 6 weeks of statin</time_frame>
    <description>Measure of oxidised low density lipoprotein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WP2: Scanning electron microscopy</measure>
    <time_frame>Baseline</time_frame>
    <description>Qualitative assessment of fibril indices</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>WP1: AF + CKD</arm_group_label>
    <description>Participants with atrial fibrillation and chronic kidney disease commencing warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP1: AF + no CKD</arm_group_label>
    <description>Participants with atrial fibrillation and no chronic kidney disease commencing warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP2: Group 1 - AF + CKD</arm_group_label>
    <description>Participants with atrial fibrillation and chronic kidney disease who are on stable doses of warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP2: Group 2 - AF + no CKD</arm_group_label>
    <description>Participants with atrial fibrillation and no chronic kidney disease who are on stable doses of warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP2: Group 3 - no AF + CKD</arm_group_label>
    <description>Participants with no atrial fibrillation and chronic kidney disease who are on stable doses of warfarin for other indications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP2: Group 4 - no AF + no CKD</arm_group_label>
    <description>Participants with no atrial fibrillation and no chronic kidney disease who are on stable doses of warfarin for other indications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WP3: AF + CKD</arm_group_label>
    <description>Participants with atrial fibrillation and chronic kidney disease who are on stable doses of warfarin and are commencing statin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>INR-dependent dosage</description>
    <arm_group_label>WP1: AF + CKD</arm_group_label>
    <arm_group_label>WP1: AF + no CKD</arm_group_label>
    <arm_group_label>WP2: Group 1 - AF + CKD</arm_group_label>
    <arm_group_label>WP2: Group 2 - AF + no CKD</arm_group_label>
    <arm_group_label>WP2: Group 3 - no AF + CKD</arm_group_label>
    <arm_group_label>WP2: Group 4 - no AF + no CKD</arm_group_label>
    <arm_group_label>WP3: AF + CKD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Any statin therapy acceptable</description>
    <arm_group_label>WP3: AF + CKD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the hospital and specialist clinics in the community
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        WP1:

          -  Diagnosed atrial fibrillation

          -  Not on anticoagulation prior to recruitment

          -  Plan to commence warfarin therapy

          -  Informed consent obtained

        WP2:

          -  Taking stable doses of warfarin with target INR of 2-3

          -  Informed consent obtained

        WP3:

          -  Statin-na√Øve at recruitment

          -  Diagnosed atrial fibrillation

          -  Taking stable doses of warfarin with target INR of 2-3

          -  Estimated glomerular filtration rate of &lt;50 ml/min/1.73m2

          -  Informed consent obtained

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Severe mitral stenosis or presence of metallic prosthetic valve

          -  Active or recent malignancy (&lt;6 months)

          -  Active immunological disease

          -  Connective tissue disease

          -  Chronic liver disease

          -  Recent or chronic serious infection

          -  Chronic inflammatory disease

          -  Known haemophilia or thrombophilia

          -  Active bleeding

          -  Untreated hypothyroidism or hyperthyroidism

          -  Recent surgery (&lt;3 months)

          -  Familial lipid disorders

          -  Concurrent use of steroids

          -  Concurrent use of non-vitamin K antagonist oral anticoagulant

          -  Dietary supplements known to influence lipids

          -  Contraindications/inability/unwillingness to commence warfarin (WP1) or statin (WP3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wern Yew Ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wern Yew Ding</last_name>
    <phone>0151 794 9020</phone>
    <email>wding@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Wilkinson</last_name>
      <phone>00441516001467</phone>
      <email>Vicky.Wilkinson@lhch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rogers</last_name>
      <phone>00441517063320</phone>
      <email>heather.rogers@rlbuht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Wern Yew Ding</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>Fibrin clot structure and function</keyword>
  <keyword>Lipids/lipoproteins</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

